1. Home
  2. IMMP vs LAW Comparison

IMMP vs LAW Comparison

Compare IMMP & LAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immutep Limited

IMMP

Immutep Limited

HOLD

Current Price

$2.63

Market Cap

264.9M

Sector

Health Care

ML Signal

HOLD

Logo CS Disco Inc.

LAW

CS Disco Inc.

HOLD

Current Price

$8.36

Market Cap

466.2M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMMP
LAW
Founded
1987
2013
Country
Australia
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
264.9M
466.2M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
IMMP
LAW
Price
$2.63
$8.36
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$7.75
AVG Volume (30 Days)
1.8M
283.2K
Earning Date
02-22-2026
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,306,742.00
$152,677,000.00
Revenue This Year
N/A
$8.51
Revenue Next Year
N/A
$7.46
P/E Ratio
N/A
N/A
Revenue Growth
31.28
6.33
52 Week Low
$1.32
$3.31
52 Week High
$3.53
$9.11

Technical Indicators

Market Signals
Indicator
IMMP
LAW
Relative Strength Index (RSI) 69.60 63.35
Support Level $2.42 $8.20
Resistance Level $2.86 $8.72
Average True Range (ATR) 0.27 0.37
MACD 0.06 0.01
Stochastic Oscillator 51.35 64.45

Price Performance

Historical Comparison
IMMP
LAW

About IMMP Immutep Limited

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

About LAW CS Disco Inc.

CS Disco Inc provides a cloud-native, artificial intelligence-powered legal solution that simplifies discovery, legal document review, and case management for enterprises, law firms, legal services providers, and governments. Its revenue-generating activities directly relate to the sale and support of legal solutions. It has two primary types of contractual arrangements: usage-based and subscription solutions. The usage-based revenue is derived from contracts under which customers are billed monthly based on their usage. Subscription revenue is derived from contracts where customers are contractually committed to a minimum data volume over a period of time.

Share on Social Networks: